Cardiovascular
1932, laboratory isolation by Vincent du Vigneaud (United States)
Hyperhomocysteinemia, understood historically as an abnormal elevation of the amino acid homocysteine in the blood, was essentially unknown to medicine until the mid-twentieth century, when biochemical advances allowed researchers to identify the compound and trace its relationship to severe vascular and metabolic disease. The condition's history was therefore compressed into a relatively short span compared to most medical conditions, unfolding rapidly across a few decades of biochemical and epidemiological investigation. Key discoveries by a small number of researchers fundamentally altered cardiovascular medicine's understanding of risk and metabolic pathology.
Historical Narrative
Unlike conditions with roots in ancient or medieval medicine, hyperhomocysteinemia had no meaningful historical presence before the twentieth century because homocysteine itself was only identified as a chemical compound in 1932, when the American biochemist Vincent du Vigneaud isolated it while studying the metabolism of the sulfur-containing amino acid methionine. Du Vigneaud's work on sulfur amino acids was part of a broader program of biochemical investigation into the building blocks of proteins, and homocysteine at that early stage was understood primarily as a laboratory curiosity and metabolic intermediate rather than as a substance of clinical consequence. Du Vigneaud's subsequent research on related compounds eventually earned him the Nobel Prize in Chemistry in 1955, though his work had not yet suggested any link between homocysteine accumulation and human disease.
The pivotal clinical insight came in the early 1960s through the work of the American physician and researcher Kilmer McCully. In 1969, McCully published a landmark paper in the American Journal of Pathology drawing on autopsy studies of children who had died from a rare inherited metabolic disorder called homocystinuria, a condition in which homocysteine accumulated dramatically in the blood due to enzymatic defects. McCully observed that these young patients displayed severe atherosclerotic changes in their arteries, resembling the vascular disease typically seen in elderly adults. He proposed the radical hypothesis that elevated homocysteine, rather than cholesterol alone, could drive arterial damage and that this mechanism might explain a portion of cardiovascular disease in the broader population.
McCully's hypothesis was poorly received by the mainstream medical and research community of the early 1970s, which was then deeply committed to the lipid hypothesis of cardiovascular disease championed by figures such as Ancel Keys. McCully found his research funding curtailed and eventually lost his position at Harvard Medical School, a chapter in medical history later cited as an example of institutional resistance to heterodox ideas. He continued his investigations with diminished resources, publishing a book titled The Homocysteine Revolution in 1997 that brought his ideas to a wider audience.
Meanwhile, the biochemical understanding of homocysteine metabolism deepened through the work of other researchers who mapped the enzymatic pathways by which methionine was converted to homocysteine and then either remethylated back to methionine or converted via a transsulfuration pathway. These studies implicated deficiencies of B vitamins, particularly folate, vitamin B6, and vitamin B12, as important determinants of homocysteine levels, since these vitamins served as cofactors for the relevant enzymes. Researchers including S. Harvey Mudd and his colleagues at the National Institutes of Health contributed substantially to characterizing the inherited enzymatic defects underlying homocystinuria and the broader population variation in homocysteine metabolism.
By the 1990s, a wave of epidemiological studies had examined whether elevated homocysteine in the general population correlated with increased rates of cardiovascular and cerebrovascular events. Studies by researchers including Meir Stampfer and colleagues, drawing on large prospective cohorts, reported associations between elevated plasma homocysteine and increased cardiovascular risk, lending epidemiological weight to McCully's earlier hypothesis. These findings generated substantial excitement and research activity, including large clinical trials designed to test whether interventions that lowered homocysteine levels would translate into reduced cardiovascular events, results from which proved complex and contested by the early 2000s, reshaping how the research community framed the condition's causal significance.
Key Historical Figures
Historical narrative only — this page describes how Hyperhomocysteinemia was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.